OncoPro EGFR Rapid Test in UAE – Real-Time PCR Mutation Detection

Executive Summary & Core Metrics

Diagnostic Accuracy: 99.9% sensitivity and 99.8% specificity for actionable EGFR mutations in NSCLC, validated under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
Specimen Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval – FFPE blocks are collected from hospital pathology departments via temperature-controlled chain; mobile home phlebotomy is not applicable for this archival tissue analysis.
Clinical Guidance: Post-test telephonic consultation included to review mutation results and therapeutic implications.
Insurance Verification: Direct coverage check via WhatsApp at +971 54 548 8731.

Test Overview & Methodology

The OncoPro EGFR Rapid Test employs real-time PCR (qPCR) to identify clinically actionable EGFR mutations (exon 19 deletions, L858R, T790M, and others) from formalin-fixed paraffin-embedded (FFPE) tumor tissue. This assay delivers next-working-day results, enabling oncologists to initiate or adjust targeted therapy with molecular precision. The methodology is optimized for low-yield FFPE specimens and includes an optional whole-genome sequencing (WGS) reflex for comprehensive resistance profiling.

Parameter	OncoPro EGFR Rapid (DNA Labs UAE)	Closest Alternative
Precision	99.9% sensitivity / 99.8% specificity	~95% sensitivity
Methodology	Real-Time PCR (qPCR) + optional WGS	Standard Sanger Sequencing
Turnaround Speed	Next working day (specimen received by 11:00 AM)	5–10 working days

Physician Insight & Safety Protocols

“This rapid EGFR assay provides the molecular clarity needed to initiate targeted therapy without unnecessary delay. In my practice, next-day results have directly improved time-to-treatment for NSCLC patients with actionable mutations. Always correlate molecular findings with clinical presentation and imaging.”

— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology | DHA Registration ID: 61713011

Advisory Notice

EGFR mutation results are intended to guide targeted therapy decisions and must be interpreted alongside full clinical, radiological, and histopathological context. Do not alter or discontinue any prescribed treatment plan without direct consultation with your treating oncologist.

Exclusion Criteria for This Assay

FFPE block tumor content < 10%
Tissue subjected to acid decalcification (e.g., bone biopsies)
Specimens fixed in non-formalin alternatives
Block compromised by improper storage or extensive necrosis

Emergency Red Flags – Seek Immediate Care

Sudden severe shortness of breath or haemoptysis
Acute chest pain or uncontrolled pain at the tumor site
Signs of serious infection (fever > 38.5°C, chills)

Patient FAQ & Clinical Guidance

1. What is the OncoPro EGFR Rapid Test and how is it performed?

This test uses real-time PCR to detect EGFR mutations from your stored FFPE tumor tissue block. A pathologist selects the appropriate block, and our courier retrieves it from the hospital laboratory. Results are reported the next working day.

2. How quickly will I receive my results and who interprets them?

Results are reported the next working day if the specimen arrives at our laboratory by 11:00 AM. A post-test telephonic consultation is included to discuss the mutation findings and their relevance to your treatment plan.

3. Is this test suitable for monitoring treatment response or resistance?

Yes, serial EGFR testing can monitor the emergence of resistance mutations such as T790M. This assists your oncologist in adjusting therapy when clinically indicated, particularly if disease progression is suspected.

4. Do I need to prepare or fast before the test?

No preparation or fasting is required. Since the test uses archival tumor tissue, no new biopsy or blood draw is needed for this analysis. Your hospital pathology department will release the FFPE block to our courier.

UAE Regulatory & Data Privacy Adherence

This diagnostic service operates in full compliance with:

Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the processing of personal health data.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – ensuring secure digital health information exchange.
Federal Decree-Law No. 4 of 2016 on Medical Liability – establishing clinical safety and patient consent standards.
ISO 9001:2015 quality management certification (Cert: INT/EGQ/2509DA/3139).

Laboratory licensed by the Dubai Health Authority (DHA) under facility license number 1143.

Clinical & Logistical Metadata

Test Name	OncoPro EGFR Rapid Test (Real-Time PCR)
Price (AED)	2,000 AED
Turnaround Time	Next Working Day (specimen received by 11:00 AM)
Sample Type / Matrix	Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block – Archival Specimen. Secure Medical Courier Solid Tissue Specimen Retrieval.
Methodology Used	Real-Time PCR (qPCR) with optional Whole-Genome Sequencing (WGS) reflex
ICD-10-CM Code	C34.90, C34.1, Z15.09
LOINC Code	21636-4
DHA Facility License & Laboratory Address	DHA License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

💬 التحقق عبر الواتساب Verify via WhatsApp 📞 Call Team

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians